RAGE Knockout BEAS-2B Cell Line

The choice depends on whether you are studying AGER (RAGE, receptor for advanced glycation end-products)'s role as a multi-ligand pattern recognition receptor or modeling its functions in diabetic complications, neurodegeneration, and airway disease. The Knockout line is the standard tool for asking whether RAGE is required for these processes — AGER/RAGE is a type I transmembrane receptor of the immunoglobulin superfamily that recognizes diverse ligands: advanced glycation end-products (AGEs, formed under hyperglycemia in diabetes), S100/calgranulin proteins, HMGB1, β-amyloid (relevant to Alzheimer's disease), DNA, RNA; RAGE engagement activates NF-κB, MAPK, and inflammatory pathways. Overexpression is useful for studying RAGE gain-of-function effects. For airway and inflammation research, the EDITGENE AGER Knockout in BEAS-2B is uniquely valuable — RAGE is one of the most highly expressed receptors in lung tissue (particularly alveolar type I cells) and is critical in COPD, idiopathic pulmonary fibrosis, asthma, and acute lung injury. RAGE has multiple splice variants including soluble RAGE (sRAGE, a decoy receptor). Rescue with wild-type, ligand-binding-deficient, or sRAGE isoform enables structure-function studies. The knockout is a critical specificity tool for ⭐⭐ azeliragon (TTP488, RAGE antagonist completing Phase III for Alzheimer's disease and diabetic complications), and emerging RAGE-targeted therapeutics in lung disease, neurodegeneration, and metabolic disease.

Primary applications: • Multi-ligand pattern recognition: AGE, HMGB1, S100A8/9, β-amyloid binding analysis in RAGE-null cells. • NF-κB activation: ligand-induced NF-κB signaling analysis given RAGE's pro-inflammatory role. • Airway disease modeling: in BEAS-2B context, characterization of RAGE-mediated airway inflammation in COPD/asthma relevance. • Azeliragon (TTP488) specificity: critical genetic control for ⭐⭐ azeliragon (RAGE antagonist Phase III for Alzheimer's disease and diabetic complications). • sRAGE biology: in heterologous expression contexts, the soluble RAGE (sRAGE) decoy receptor function. EDITGENE recommends this BEAS-2B-based model for researchers investigating AGER/RAGE biology in airway disease and emerging RAGE-targeted therapeutic development.

Yes. RAGE rescue experiments are well-established for pattern recognition receptor research: • Construct design: use a codon-modified AGER sequence with a small intracellular C-terminal tag (FLAG, HA). RAGE has extracellular V-type Ig (ligand binding), C1, C2 Ig-like domains, transmembrane span, and intracellular signaling tail (the ddRAGE tail mediates pro-inflammatory signaling) — preserve all elements. • Surface localization validation: confirm plasma membrane RAGE by cell surface staining before ligand binding studies. • Ligand-binding-deficient rescue: V-domain mutations disrupt ligand binding. • sRAGE rescue: soluble RAGE (lacking transmembrane domain, secreted) generates a decoy receptor — useful for studying sRAGE biology. • Functional readout: rescue should restore RAGE-ligand-induced NF-κB activation. BEAS-2B-specific considerations: • BEAS-2B is a SV40-immortalized normal human bronchial epithelial cell line — widely used for respiratory epithelial biology, airway inflammation, COPD, and asthma research. • Lentiviral transduction is supported but may require optimization compared to standard transformed cell lines. • BEAS-2B retains bronchial epithelial features and is highly relevant for AGER/RAGE airway disease research.